Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Thrombocythemia, Essential Clinical Trial

Official title:
An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)

Status Recruiting

Clinical Trial Summary

This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04081220
Study type	Interventional
Source	The University of Texas Health Science Center at San Antonio
Contact	Epp Goodwin
Phone	210-450-5798
Email	goodwine@uthscsa.edu
Status	Recruiting
Phase	Phase 2
Start date	April 9, 2020
Completion date	January 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02912884` - Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
Completed	`NCT00567502` - Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments
Recruiting	`NCT06351631` - A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)	Phase 3
Recruiting	`NCT01816022` - Myeloproliferative Neoplasms and Bone Structure	N/A
Active, not recruiting	`NCT05223920` - Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)	Phase 2
Terminated	`NCT00522574` - A Safety Study of XL019 in Adults With Myelofibrosis	Phase 1
Completed	`NCT01134120` - A Study in Myeloproliferative Disorders	Phase 1